Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 35c

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.21, $0.35 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.47 million versus the consensus estimate of $52.06 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley Resumes Global Payments (GPN) at Equalweight
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group